statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

-- Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels -- -- Lp(a) Results Published Simultaneously in the Journal of the...

New REDUCE-IT  Analyses Show VASCEPA /VAZKEPA  (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

Company's IP Protection for VAZKEPA in Europe Now Extended Into 2039DUBLIN, Ireland and BRIDGEWATER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced...

Amarin Provides Update on VAZKEPA  (Icosapent Ethyl) Intellectual Property Portfolio in Europe

Any one-product company that receives good news about that product will likely attract investors. That was the case Wednesday with Amarin (NASDAQ: AMRN), which received very encouraging news about...

Why Amarin Stock Was Rocketing Higher on Wednesday

Amarin Co. plc (NASDAQ:AMRN  Free Report)  Zacks Research boosted their Q1 2024 earnings per share (EPS) estimates for Amarin in a research report issued to clients and investors on...

Research Analysts Offer Predictions for Amarin Co. plc's Q1 2024 Earnings (NASDAQ:AMRN)

-- Subgroup Analyses from REDUCE-IT and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -- DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024...

Research Evaluating Benefits of VASCEPA /VAZKEPA  (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo

Amarin Co. plc (NASDAQ:AMRN  Free Report)  Investment analysts at Cantor Fitzgerald raised their FY2024 earnings estimates for Amarin in a note issued to investors on Monday, March...

FY2024 EPS Estimates for Amarin Co. plc Increased by Cantor Fitzgerald (NASDAQ:AMRN)

Q4 2023 Amarin Corporation PLC Earnings Call Transcript

-- Company Delivers Total Revenues of $75 Million in the Fourth Quarter and $306 Million for the Full-Year 2023 ---- Reaffirms Year-End 2023 Cash Position of $321 Million and Full-Year Positive Cash...

Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript...

Amarin Corporation plc (AMRN) Q4 2023 Earnings Call Transcript

Amarin Co. plc (NASDAQ:AMRN  Get Free Report) traded up 9.9% on Tuesday . The company traded as high as $1.34 and last traded at $1.33. 1,111,735 shares traded hands during mid-day trading, a...

Amarin (NASDAQ:AMRN) Shares Up 9.9%

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Watchers	31,130
52-Wk Low	$0.651
52-Wk High	$1.49

Volume	454,830.00
52-Wk High	$1.49
52-Wk Low	$0.651

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.04	--	--	N/A
Q1'24	-$0.03	-$0.02	33.33%	BEAT
Q4'23	-$0.03	-$0.01	62.80%	BEAT
Q3'23	-$0.05	-$0.05	-11.11%	MISSED
Q2'23	-$0.04	-$0.04	--	EXPECTED

AMRN Amarin Corp - ADR

About

Feed

News

Sentiment

Earnings

Fundamentals